Immunoglobulin Replacement Therapy Guidelines

Indications for IVIG Therapy

The National Comprehensive Cancer Network (NCCN) recommends monthly 400-500 mg/kg IVIG replacement for select patients with hypogammaglobulinemia (those with serum IgG levels <400-600 mg/dL AND serious or recurrent infections) 2, 3
IVIG replacement therapy is indicated for patients who meet any of the following criteria: IgG levels <400 mg/dL 1, 3
Patients who have experienced ≥2 severe recurrent infections by encapsulated bacteria, regardless of IgG level 1
Patients with a life-threatening infection 1
Patients with documented bacterial infection with no or insufficient response to antibiotic therapy 1

IVIG should be continued until serum IgG levels normalize and infections are resolved 2
The patient's current IgG level (758 mg/dL) exceeds the threshold of 400-600 mg/dL recommended for IVIG therapy 1, 2, 3
Monitor IgG levels every 1-3 months 1

IVIG therapy carries potential risks including headache, aseptic meningitis, and anaphylaxis 4

This recommendation aligns with current standard of care based on NCCN guidelines for management of immunotherapy-related toxicities 2, 3
Expert panel consensus recommendations for monitoring, prophylaxis, and treatment of infections in patients receiving bispecific antibody therapy 1